NDTP — NDT Pharmaceuticals Share Price
Last trade - 00:00- $16.00m
- $15.94m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 22.28 | ||
| Price to Tang. Book | 22.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | -4,452.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -14.31% | ||
| Return on Equity | -31.55% | ||
| Operating Margin | 2859.37% | ||
Financial Summary
| Year End 31st Dec | Unit | 2007 | 2008 | 2009 | 2010 | 2011 | 2012E | 2013E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.03 | 0.01 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NDT Pharmaceuticals, Inc. is a Canada-based company, which is focused on developing nutraceutical and pharmaceutical products utilizing intellectual property. The Company has acquired all rights under a Sponsored Research Agreement with the University of Pennsylvania, including rights to use the University's Nanoscale Particle Complex (NPC) technology. The intellectual property includes a versatile and widely applicable biotechnology asset base, including the Nanoscale Particle Complex (NPC) technology, which represents phospholipid-based nano-encapsulation delivery systems that create instant delivery of payloads into the bloodstream, beginning through the membranes of the mouth. The NPC technology also incorporates a potent active ingredient that stimulates repair of damaged cell tissue branded by the Company as Cell Armor.
Directors
- Last Annual
- December 31st, 2011
- Last Interim
- September 30th, 2012
- Incorporated
- May 13th, 2005
- Public Since
- December 14th, 2006
- No. of Employees
- 1
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 160,004,349
- Address
- Suite 809-4438 West 10Th Avenue, VANCOUVER, V6R 4R8
- Web
- Phone
- +1 6046894088
- Auditors
- James Stafford
Upcoming Events for NDTP
Similar to NDTP
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:15 UTC, shares in NDT Pharmaceuticals are trading at $0.15. This share price information is delayed by 15 minutes.
Shares in NDT Pharmaceuticals last closed at $0.15 and the price had moved by -84.85% over the past 365 days. In terms of relative price strength the NDT Pharmaceuticals share price has underperformed the S&P500 Index by -87.28% over the past year.
There is no consensus recommendation for this security.
NDT Pharmaceuticals does not currently pay a dividend.
NDT Pharmaceuticals does not currently pay a dividend.
NDT Pharmaceuticals does not currently pay a dividend.
To buy shares in NDT Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.15, shares in NDT Pharmaceuticals had a market capitalisation of $24.00m.
Here are the trading details for NDT Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NDTP
Based on an overall assessment of its quality, value and momentum NDT Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NDT Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +114.59%.
As of the last closing price of $0.15, shares in NDT Pharmaceuticals were trading -89.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NDT Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NDT Pharmaceuticals' management team is headed by:
- Kent Carasquero - CEO